Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Recombinant HPV16/18 Bivalent Vaccine (E. coli)
CTR20130951Phase 3Active
- Sponsor
- Xiamen University
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human papillomavirus 16/18 bivalent vaccine in HPV16 infection (HPV16), human papillomavirus infection, Cervical Cancer (CC), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VAIN), sponsored by Xiamen University. Started Jun 2015; status: active.
02
Drugs
human papillomavirus 16/18 bivalent vaccine
03
Conditions
HPV16 infection (HPV16)human papillomavirus infectionCervical Cancer (CC)vulvar intraepithelial neoplasia (VIN)vaginal intraepithelial neoplasia (VAIN)
Beyond the preview
Go deeper on CTR20130951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130951.